Prostate Cancer clinical trials
Showing 451–500 of 735 active trials. Describe your situation to see which ones you may be eligible for.
- Geriatric Assessment and Technology Evaluation in Prostate Cancer
- ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
- Longitudinal Advanced Prostate Cancer Cohort (LAPCC)
- Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment
- Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe
- Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
- Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
- Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing
- Outcomes of Focal Ablation for Prostate Cancer
- Phase I Human Analytics (HALO) Study
- MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- Tumor Microenvironment Analysis of Prostate Cancer Metastasis
- Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
- MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
- FTT PET/CT in Metastatic Prostate Cancer
- Prostate Cancer Genetic Risk Evaluation and Screening Study
- Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
- Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI
- PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
- MRI-Guided Cryoablation for Focal Native Prostate Cancer
- Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
- Precision-Based Genomics in Prostate Cancer
- Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
- Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
- Active Surveillance SNEP Assay Registry Trial for Prostate Cancer
- Men at High Genetic Risk for Prostate Cancer
- EDRN Prostate MRI Biomarker Study
- HIFU for Focal Ablation of Prostate Tissue: An Observational Study
- Upright MRI for Prostate Cancer Screening
- Ablative Therapy in the Management of Prostate Cancer
- Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
- International Registry for Men With Advanced Prostate Cancer (IRONMAN)
- Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients
- Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
- MRI/Ultrasound Fusion Guided Prostate Cryotherapy
- Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
- Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
- Active Surveillance for Cancer of the Prostate (ASCaP)
- Collection of Blood From Patients With Prostate Cancer
- Prostate Active Surveillance Study
- A Study of a New PET Scanner in People With Cancer
- Screening and Staging of Benign vs Malignant Pelvic Abnormalities
- Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
- Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Urologic Lymphadenectomy in AMIGO
- A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- Sample Collection for Ongoing Research and Product Evaluation Study
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.